KR100372988B1 - 보리코나졸 함유 제약 제제 - Google Patents

보리코나졸 함유 제약 제제 Download PDF

Info

Publication number
KR100372988B1
KR100372988B1 KR10-1999-7012034A KR19997012034A KR100372988B1 KR 100372988 B1 KR100372988 B1 KR 100372988B1 KR 19997012034 A KR19997012034 A KR 19997012034A KR 100372988 B1 KR100372988 B1 KR 100372988B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical formulation
formula
voriconazole
cyclodextrin
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR10-1999-7012034A
Other languages
English (en)
Korean (ko)
Other versions
KR20010014006A (ko
Inventor
발레리 데니스 하딩
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10814734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100372988(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20010014006A publication Critical patent/KR20010014006A/ko
Application granted granted Critical
Publication of KR100372988B1 publication Critical patent/KR100372988B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR10-1999-7012034A 1997-06-21 1998-06-02 보리코나졸 함유 제약 제제 Expired - Lifetime KR100372988B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9713149.4 1997-06-21
GBGB9713149.4A GB9713149D0 (en) 1997-06-21 1997-06-21 Pharmaceutical formulations
PCT/EP1998/003477 WO1998058677A1 (en) 1997-06-21 1998-06-02 Pharmaceutical formulations containing voriconazole

Publications (2)

Publication Number Publication Date
KR20010014006A KR20010014006A (ko) 2001-02-26
KR100372988B1 true KR100372988B1 (ko) 2003-02-25

Family

ID=10814734

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1999-7012034A Expired - Lifetime KR100372988B1 (ko) 1997-06-21 1998-06-02 보리코나졸 함유 제약 제제

Country Status (47)

Country Link
US (1) US6632803B1 (enExample)
EP (1) EP1001813B8 (enExample)
JP (2) JP2000513029A (enExample)
KR (1) KR100372988B1 (enExample)
CN (1) CN1125653C (enExample)
AP (1) AP912A (enExample)
AR (1) AR015900A1 (enExample)
AT (1) ATE238812T1 (enExample)
AU (1) AU724799B2 (enExample)
BG (1) BG64584B1 (enExample)
BR (1) BRPI9809468B8 (enExample)
CA (1) CA2295035C (enExample)
CO (1) CO4940450A1 (enExample)
CZ (1) CZ289570B6 (enExample)
DE (1) DE69814091T2 (enExample)
DK (1) DK1001813T3 (enExample)
DZ (1) DZ2523A1 (enExample)
EA (1) EA001924B1 (enExample)
EG (1) EG23910A (enExample)
ES (1) ES2195355T3 (enExample)
GB (1) GB9713149D0 (enExample)
HR (1) HRP980341B1 (enExample)
HU (1) HU228338B1 (enExample)
ID (1) ID22939A (enExample)
IL (1) IL132918A (enExample)
IS (1) IS2004B (enExample)
MA (1) MA26508A1 (enExample)
ME (1) ME00907B (enExample)
MY (1) MY118151A (enExample)
NO (1) NO313125B1 (enExample)
NZ (1) NZ501066A (enExample)
OA (1) OA11232A (enExample)
PA (1) PA8453201A1 (enExample)
PE (1) PE84899A1 (enExample)
PL (1) PL191295B1 (enExample)
PT (1) PT1001813E (enExample)
RS (1) RS49633B (enExample)
SA (1) SA98190159B1 (enExample)
SI (1) SI1001813T1 (enExample)
SK (1) SK282946B6 (enExample)
TN (1) TNSN98090A1 (enExample)
TR (1) TR199903191T2 (enExample)
TW (1) TW406023B (enExample)
UA (1) UA57083C2 (enExample)
UY (1) UY25055A1 (enExample)
WO (1) WO1998058677A1 (enExample)
ZA (1) ZA985364B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101290626B1 (ko) * 2008-12-31 2013-07-29 용시앙 주 보리코나졸이 포함된 약물 제제 및 그 제조 방법

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818258D0 (en) * 1998-08-21 1998-10-14 Pfizer Ltd Antifungal compositions
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
UA79984C2 (en) * 2002-08-20 2007-08-10 Bristol Myers Squibb Co Preparation on the basis of aripiprazole complex and use thereof
GB0327390D0 (en) * 2003-11-25 2003-12-31 Pfizer Ltd Pharmaceutical formulations
US20050176696A1 (en) * 2003-12-08 2005-08-11 Regents Of The University Of Arizona Synergistic anit-cancer compounds
EP1765336A4 (en) 2004-06-25 2010-03-10 Univ Johns Hopkins ANGIOGENESIS INHIBITORS
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US20070082870A1 (en) * 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
AR061889A1 (es) 2006-07-13 2008-10-01 Medichem Sa Proceso mejorado para la preparacion de voriconazol
CN1919846B (zh) * 2006-09-14 2013-01-02 大道隆达（北京）医药科技发展有限公司 伏立康唑及其药用盐、中间体的一种新定向合成制备方法
BG1110U1 (bg) * 2007-06-19 2008-09-30 Рудолф ПОДЛИПСКИ Отоплителен съд за експресно локално загряване навода
EP2018866A1 (en) * 2007-07-27 2009-01-28 Sandoz AG Pharmaceutical compositions containing voriconazole
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
WO2009137611A2 (en) * 2008-05-06 2009-11-12 Board Of Regents, The University Of Texas System Treatment of pulmonary fungal infection with voriconazole via inhalation
WO2010084505A2 (en) * 2008-06-06 2010-07-29 Glenmark Pharmaceuticals Limited Stable topical formulation comprising voriconazole
CN101390825B (zh) * 2008-10-01 2010-12-29 山东省眼科研究所 一种伏立康唑眼内释药系统
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
WO2011020605A1 (en) 2009-08-19 2011-02-24 Ratiopharm Gmbh Process for the production of coevaporates and complexes comprising voriconazole and cyclodextrin
WO2011064558A2 (en) 2009-11-30 2011-06-03 Cipla Limited Pharmaceutical composition
DK3391890T3 (da) 2010-06-29 2021-11-01 Merck Sharp & Dohme Intravenøse posaconazolopløsningsformuleringer, der er stabiliseret ved hjælp af substitueret beta-cyclodextrin
EP2409699B1 (en) 2010-07-23 2014-04-30 Combino Pharm, S.L. Stable compositions of voriconazole
CN102058519B (zh) * 2010-11-19 2013-01-02 苏州特瑞药业有限公司 一种伏立康唑缓释栓剂及其制备方法
WO2012171561A1 (en) 2011-06-15 2012-12-20 Synthon Bv Stabilized voriconazole composition
EP2561863A1 (en) 2011-08-22 2013-02-27 Farmaprojects, S.A.U. Pharmaceutical compositions comprising voriconazole
WO2013103924A2 (en) * 2012-01-05 2013-07-11 Guilford Frederick Timothy Liposomally encapsulated reduced glutathione for management of cancer, including with other pharmaceutical compositions
US8853248B2 (en) 2012-04-05 2014-10-07 Hubert Maehr (1,2,3-triazolyl)sulfonyl derivatives
MX364393B (es) 2012-05-08 2019-04-24 Onyx Therapeutics Inc Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico.
RU2014149993A (ru) 2012-05-11 2016-07-10 Сипла Лимитед Фармацевтическая композиция
ES2780363T3 (es) 2013-01-11 2020-08-25 Xellia Pharmaceuticals Aps Complejos de inclusión de voriconazol
WO2014182368A2 (en) 2013-03-14 2014-11-13 Fresenius Kabi Usa, Llc Voriconazole formulations
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
CN103690968A (zh) * 2013-11-21 2014-04-02 石药集团中奇制药技术（石家庄）有限公司 一种伏立康唑组合物及其制备方法
PT109117B (pt) * 2016-01-28 2019-02-01 Hovione Farm Sa Complexação de ingredientes ativos farmacêuticos
CA3043979A1 (en) 2016-11-18 2018-05-24 Aicuris Anti-Infective Cures Gmbh Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
US11040958B2 (en) 2017-02-17 2021-06-22 Wuhan Ll Science And Technology Development Co., Ltd. Triazole antimicrobial derivative, pharmaceutical composition and use thereof
CN113750034A (zh) * 2020-06-05 2021-12-07 中南大学湘雅三医院 耳用温敏凝胶及其制备方法
CN116570558B (zh) * 2023-06-21 2023-12-26 广州仁恒医药科技股份有限公司 一种伏立康唑眼用纳米缓释组合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440372A1 (en) * 1990-02-02 1991-08-07 Pfizer Limited Triazole antifungal agents
WO1991011172A1 (en) * 1990-01-23 1991-08-08 The University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DE3347421A1 (de) 1983-12-29 1985-07-11 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von fluorarmen alkaliphosphatloesungen
GB8819308D0 (en) 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GB9512961D0 (en) 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011172A1 (en) * 1990-01-23 1991-08-08 The University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0440372A1 (en) * 1990-02-02 1991-08-07 Pfizer Limited Triazole antifungal agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101290626B1 (ko) * 2008-12-31 2013-07-29 용시앙 주 보리코나졸이 포함된 약물 제제 및 그 제조 방법

Also Published As

Publication number Publication date
BR9809468B1 (pt) 2013-11-12
AP912A (en) 2001-12-08
IL132918A0 (en) 2001-03-19
BG103882A (en) 2000-07-31
EP1001813A1 (en) 2000-05-24
JP5089004B2 (ja) 2012-12-05
KR20010014006A (ko) 2001-02-26
YU68199A (sh) 2002-06-19
CO4940450A1 (es) 2000-07-24
ATE238812T1 (de) 2003-05-15
TW406023B (en) 2000-09-21
HU228338B1 (en) 2013-03-28
OA11232A (en) 2003-05-26
PL337692A1 (en) 2000-08-28
BG64584B1 (bg) 2005-08-31
IS5248A (is) 1999-11-15
CA2295035C (en) 2005-04-19
AU8110498A (en) 1999-01-04
SK159399A3 (en) 2000-06-12
HK1027966A1 (en) 2001-02-02
CZ289570B6 (cs) 2002-02-13
ZA985364B (en) 1999-12-20
ES2195355T3 (es) 2003-12-01
MY118151A (en) 2004-09-30
NO313125B1 (no) 2002-08-19
AU724799B2 (en) 2000-09-28
DE69814091T2 (de) 2004-01-22
NZ501066A (en) 2001-01-26
EP1001813B1 (en) 2003-05-02
SA98190159B1 (ar) 2005-12-21
NO995565L (no) 1999-11-30
PE84899A1 (es) 1999-09-17
ME00907B (me) 2007-08-03
DE69814091D1 (de) 2003-06-05
BR9809468A (pt) 2000-06-20
HRP980341A2 (en) 1999-02-28
JP2000513029A (ja) 2000-10-03
SK282946B6 (sk) 2003-01-09
SI1001813T1 (en) 2004-02-29
UA57083C2 (uk) 2003-06-16
EG23910A (en) 2007-12-30
AP9801268A0 (en) 1998-06-30
CA2295035A1 (en) 1998-12-30
GB9713149D0 (en) 1997-08-27
RS49633B (sr) 2007-08-03
NO995565D0 (no) 1999-11-12
US6632803B1 (en) 2003-10-14
ID22939A (id) 1999-12-16
EA199900937A1 (ru) 2000-08-28
PL191295B1 (pl) 2006-04-28
JP2002332234A (ja) 2002-11-22
CN1261287A (zh) 2000-07-26
BRPI9809468B8 (pt) 2022-01-18
HUP0003323A3 (en) 2002-01-28
DZ2523A1 (fr) 2003-02-01
TR199903191T2 (xx) 2000-09-21
IL132918A (en) 2001-09-13
HUP0003323A2 (hu) 2001-06-28
TNSN98090A1 (fr) 2005-03-15
HRP980341B1 (en) 2001-12-31
PT1001813E (pt) 2003-07-31
IS2004B (is) 2005-04-15
CZ409699A3 (cs) 2000-02-16
DK1001813T3 (da) 2003-07-28
AR015900A1 (es) 2001-05-30
PA8453201A1 (es) 2000-05-24
UY25055A1 (es) 2000-12-29
EP1001813B8 (en) 2014-02-12
MA26508A1 (fr) 2004-12-20
EA001924B1 (ru) 2001-10-22
WO1998058677A1 (en) 1998-12-30
CN1125653C (zh) 2003-10-29

Similar Documents

Publication Publication Date Title
KR100372988B1 (ko) 보리코나졸 함유 제약 제제
US6133248A (en) Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof
KR100708360B1 (ko) 라스-파르네실트란스퍼라제 억제제와술포부틸에테르-7-β-시클로덱스트린 또는2-히드록시프로필-β-시클로덱스트린과의 착물 및 방법
JP4215277B2 (ja) シクロデキストリンを含有する薬学的組成物用防腐剤系
WO1996032135A1 (en) Pharmaceutical composition
CA2486571C (en) Pharmaceutical composition
MXPA99012075A (en) Pharmaceutical formulations containing voriconazole
HK1027966B (en) Pharmaceutical formulations containing voriconazole
JPH02172913A (ja) ポリプレニル系化合物含有注射剤
JP2005527615A (ja) ナトリウムチャンネルブロッカーの非経口適用のための新規な製剤

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 19991220

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20020228

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20030106

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20030207

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20030210

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20060106

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20070108

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20080110

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20090114

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20100113

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20110201

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20120131

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20130130

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20130130

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20140129

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20140129

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20150129

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20150129

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20151230

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20151230

Start annual number: 14

End annual number: 14

FPAY Annual fee payment

Payment date: 20161229

Year of fee payment: 15

PR1001 Payment of annual fee

Payment date: 20161229

Start annual number: 15

End annual number: 15

FPAY Annual fee payment

Payment date: 20171228

Year of fee payment: 16

PR1001 Payment of annual fee

Payment date: 20171228

Start annual number: 16

End annual number: 16

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20190611

Termination category: Expiration of duration